- Buys
- 1 of 4
- Three are needed, so CVS Health stays out of the basket.
- Free cash flow yield on guidance
- 10.6%
- 2026 operating cash flow guidance less trailing capex, over a $116.96B market cap.
- Gross debt less cash
- $48.94B
- $11.73B if every investment the insurer holds counted as free.
- Aetna medical benefit ratio
- 91.3%
- Third quarter, down from 92.8% a year earlier.
Durable quality, long horizonCheap on normal cash flow, but regulators set the prices and the capital record is poor.
Deep value, margin of safetyFive-year average earnings at 10x come to about half the market cap.
Macro and reflexivityThe pricing cycle has turned and the breakup puts a date on a re-rating.
Growth investingTimed out, so no vote was cast.
Session of November 4, 2026. Three seats voted; Investor D timed out. We could not open the separation 8-K, so its terms come from press reports. This is the first CVS Health review.
Bottom line
CVS Health posted a clean quarter and announced a breakup the same morning. We think the cash case beats the five-year record. Guidance now calls for 2026 operating cash flow of at least $15.5B, up from at least $11.5B. On that base the market cap assumes free cash flow shrinks about 4.2% a year for a decade. That is gloomy for a company that just raised its outlook.
The record is why nobody is rushing. Revenue grew 8.3% a year from 2021 to 2025 while operating income fell 23.1% a year. One seat calls the latest quarter the end of that story. Two call it one good year from a management team still owed proof.
The first test is the 2026 annual report, due by March 1, 2027. Operating cash flow below $15.5B there would break two of the three theses at once.
The business in 60 seconds
CVS runs three segments (10-Q, filed November 4, 2026). Health Services, the Caremark pharmacy benefit manager plus specialty pharmacy and the Oak Street and Signify care businesses, had $53.96B of third-quarter revenue, up 9.5%. Health Care Benefits, which is Aetna, had $36.85B, up 2.4%. Pharmacy and Consumer Health, roughly 9,000 drugstores, had $35.50B, down 2.0%.
Segment operating income is not tagged in the filings. The release credits the quarter's improvement mainly to Aetna (8-K Exhibit 99.1, filed November 4, 2026). Goodwill of $85.48B and intangibles of $24.22B exceed equity of $80.50B, so tangible book is negative $29.20B. The proxy's holder table (DEF 14A, filed April 3, 2026) would not load for us today, and nothing we read shows a controlling holder or a second share class.
| Fiscal year | Revenue | Operating margin | Free cash flow | Diluted shares |
|---|---|---|---|---|
| 2021 | $292.1B | 4.6% | $15.7B | 1.3B |
| 2022 | $322.5B | 2.5% | $13.4B | 1.3B |
| 2023 | $357.8B | 3.8% | $10.4B | 1.3B |
| 2024 | $372.8B | 2.3% | $6.3B | 1.3B |
| 2025 | $402.1B | 1.2% | $7.8B | 1.3B |
10-K fiscal year rows, SEC EDGAR. 2025 carries a $5.7B goodwill impairment.
What changed
- Results. Third-quarter revenue was $108.4B, up 5.4%, and operating income $3.57B against a loss a year earlier (8-K Exhibit 99.1, filed November 4, 2026).
- Guidance raised. Adjusted EPS to at least $8.20 from $7.90 to $8.10, GAAP diluted EPS to at least $6.98, operating cash flow to at least $15.5B from at least $11.5B (same exhibit). P/E: at most 13.1x GAAP, 11.1x adjusted.
- A breakup. One company would hold Aetna, Caremark, specialty pharmacy, Oak Street and Signify. The other would hold the stores, mail order and MinuteClinic. Completion is targeted for the first half of 2028, structured to be tax-free (reported by CNBC and Reuters, November 4, 2026).
- Peers. UnitedHealth's third-quarter earnings from operations rose to $6.6B from $4.32B, with a medical cost ratio of 88.4% (8-K, filed October 13, 2026). Elevance raised its outlook but booked a large accrual for a February 27, 2026, CMS notice on past Medicare Advantage risk adjustment data (8-K, filed October 21, 2026), a program Aetna also lives on.
The bull case on CVS Health
- The cash is large even in bad years. Free cash flow bottomed at $6.3B in 2024. Guidance implies about $12.4B for 2026.
- The turn is industry-wide. Aetna's 150 basis point ratio improvement came in the same season as a 52.1% jump in UnitedHealth's operating earnings.
- The growth engine stays with the insurer. Health Services is up 10.6% over nine months. The shrinking stores go to the other company.
- The split forces disclosure. Separation filings must put debt and dividend policy on file.
Neglect is the setup.
Investor C, Buy, on 1.27% short interest and no insider filings in 90 days
If Aetna's repricing holds, normalized cash earnings are nearer the five-year average than the recent lows.
Investor A, Watch, on why it is watching
The bear case on CVS Health
- Growth never reached the owners. Free cash flow fell 16.1% a year from 2021 to 2025, and incremental return on invested capital was negative 33.0%.
- No asset floor. The equity is mostly the price of past deals, and one was written down by $5.7B a year ago.
- The float is not the parent's cash. Net debt is $11.73B counting all $37.22B of investments, $48.94B counting cash alone, plus $14.62B of operating leases.
- The regulator holds the pricing. Item 1A lists CMS audits, Star ratings and retroactive premium adjustments (10-K, filed February 10, 2026).
That is a business that grew bigger and less profitable at the same time.
Investor A, Watch, on the five-year record
my cycle read would be the same head-fake that trapped earlier buyers of this name.
Investor C, Buy, naming how its own thesis fails
Where the committee splits
Three seats answered and landed in three places.
Is the Aetna recovery a cycle turn or one good year?
| Position | Seats | The figure it rests on |
|---|---|---|
| The cycle has turned | C | Benefit ratio 91.3% against 92.8%, company release, November 4, 2026 |
| The record outweighs a quarter | A, B | Operating income down 23.1% a year, 10-K rows 2021 to 2025 |
What settles it. The Aetna benefit ratio in each 2027 10-Q. At or above 92.8%, both A's and C's theses break.
From the chair, to Investor C. Your weakest link says the record contradicts this inflection. How many 2027 quarters below 91.3% would you need, before separation terms arrive, to hold Buy?
What is a normal year of earnings?
| Position | Seats | The figure it rests on |
|---|---|---|
| Five-year average net income, $5.40B | B | 10-K rows 2021 to 2025 |
| Guided cash flow, about $12.4B | A, C | 8-K, November 4, 2026 |
What settles it. 2026 net income in the annual report, against the $11.70B B named.
From the chair, to Investor B. Your average keeps 2025, which carries a $5.7B impairment, while 2026 GAAP EPS is guided to at least $6.98. If the annual report confirms that, which year leaves the normalization, and why does the impairment year stay?
Does the breakup release value or leak it?
| Position | Seats | The figure it rests on |
|---|---|---|
| A dated catalyst | C | First half of 2028 target, press reports, November 4, 2026 |
| Terms unknown, dis-synergies likely | A, B | Debt allocation, dividend and costs, not on file |
What settles it. The separation filings. C breaks if more than half of the $60.68B gross debt goes to the retail company.
From the chair, to Investor A. You call capital allocation the link no cycle repairs. What would the separation filings need to show on debt and the combined dividend to move that link to supported?
| Investor | Verdict | What breaks its thesis |
|---|---|---|
| A | Watch 6 | 2026 operating cash flow under $15.5B, which moves it to Avoid. A 2027 ratio at or above 92.8%. An impairment above $1B before the split. Critical: government reimbursement. |
| B | Avoid 8 | 2026 net income, or operating cash flow less D&A, of at least $11.70B forces a rethink. Critical: medical costs against premiums. |
| C | Buy 6 | 2026 operating cash flow under $15.5B. A 2027 ratio at or above 92.8%. Over half the debt on retail. High yield spread above 4.50% through March 1, 2027. Critical: the pricing cycle; cost trend reasserting flips it to Sell. |
Valuation
What the price requires. This is our arithmetic, which the seats never saw. At a 9.41% discount rate, 4.5 points over the 10-year yield, the market cap needs trailing free cash flow of $15.57B to shrink 7.4% a year for ten years, then grow 3%. Year three lands at $12.37B, in a band of $11.65B to $13.05B a point either side.
Trailing cash flow runs about $3.1B ahead of guidance, so we reran it on the guided base. The required decline becomes 4.2% a year, and year three needs $10.27B at 8.41%, $10.92B at 9.41% and $11.54B at 10.41%. We use the guided base from here. On enterprise value the guided yield is 9.7% counting every investment and 7.5% counting cash only, against a 4.91% 10-year Treasury yield.
Hatched rows show the hurdle. Seat rows weight each seat's own three cases.
| Investor | Bear | Base | Bull | Weighted, year 3 | Against the price |
|---|---|---|---|---|---|
| A | 30%, $6B to $8B | 50%, $11B to $13B | 20%, $15B to $16B | $11.2B | inside the band |
| B | 30%, $6.3B | 50%, $10.4B | 20%, $15.7B | $10.2B | below the band |
| C | 25%, $7.5B | 50%, $13B | 25%, $16B | $12.4B | above the band |
Ranges enter the weighted column at their midpoint.
The seats sort as they voted. C expects more cash than the price needs and voted Buy. B sits under the band. A sits inside it, and says the arithmetic is not what holds it back:
A management team that has reinvested at negative incremental returns and now proposes a complex separation with undisclosed terms cannot be fixed by the cycle, and it is the reason this stays on my watch list rather than in the portfolio.
Investor A, Watch
| Investor | Entry discipline |
|---|---|
| A | 12% free cash flow yield on five-year average cash flow, or above 10.6% on guidance once separation filings show conservative debt allocation. |
| B | At most 7x verified normalized earnings. |
| C | 12% guided free cash flow yield, or at most 11.1x guided adjusted EPS once debt and dividend policy are on file. |
Comparables
| Company | Market cap | Growth last FY | Operating margin | P/E | FCF yield |
|---|---|---|---|---|---|
| CVS Health (CVS) | $117.0B | 7.8% | 1.2% | 10.6x | 13.3% |
| UnitedHealth (UNH) | $362.4B | 11.8% | 4.2% | 22.8x | 6.3% |
| Elevance (ELV) | $89.4B | 12.5% | 3.6% | 17.4x | 7.3% |
| Cigna (CI) | $78.1B | 11.2% | 3.3% | 12.2x | n/a |
SEC filings and a Yahoo Finance price, one method for all four. The CVS yield is trailing, above its guidance.
Enterprise value over after-tax operating income is 9.4x at CVS, 10.2x at Cigna, 17.0x at UnitedHealth and 24.8x at Elevance. Humana is left out: its row showed a 46.4% operating margin, a data error.
CVS grew slowest and kept about a third of its peers' margin, so some discount is deserved. Cigna, whose Evernorth unit competes with Caremark, trades only a little above it on earnings.
Key risks
The desk ranked these. Raised by shows where each appeared.
| Risk | Why it matters | Raised by | First signal |
|---|---|---|---|
| High. CMS rates and risk adjustment | Decides whether Aetna's repricing sticks | 10-K Item 1A; Analyst; Investors A, C | A CMS notice naming Aetna |
| High. Cost trend outruns premiums | One point of benefit ratio swings group profit | Investors B, C; Analyst | 2027 ratio at or above 92.8% |
| High. Separation debt and dis-synergies | The three units trade heavily with each other | Investors A, B, C; Analyst | Over half the debt on retail |
| High. Pharmacy benefit reform | Health Services is the largest, fastest segment | Analyst; FTC talks reported by Stock Titan, not confirmed in a filing | Final FTC terms |
| Medium. Leverage without the float | Net debt depends on what the insurer can release | Desk arithmetic; Investor B | Parent liquidity in separation filings |
| Medium. Capital allocation | Overpaying for growth is the bears' history | Investor A; Analyst; forum (unverified) | An impairment above $1B |
A Justice Department dispensing settlement of October 13, 2026, was reported as already reserved, which we have not seen in a filing.
What to watch
| Date | Event | What it decides |
|---|---|---|
| By March 1, 2027 | 2026 annual report, SEC deadline for a large accelerated filer | Cash flow against $15.5B; B's net income test |
| Ongoing | 2027 quarterly filings | Benefit ratio against 92.8% |
| Ongoing | Separation filings, date not set | Debt, dividend, costs |
| First half of 2028 | Separation target, company announcement, November 4, 2026 | Whether both halves stand alone |
Owning it onchain
Two tokenized versions exist. The Backpack token is not investable: it is not verified on Jupiter. We have not judged the xStocks token: when we checked, before regular US trading opened on November 4, 2026, no market maker would quote a sale back.
Data
| Item | Figure | Source |
|---|---|---|
| Price | $91.41 | Yahoo Finance close, November 3, 2026 |
| Shares outstanding | 1,279,474,188 | SEC EDGAR, as of October 28, 2026 |
| Market cap | $116.96B | Price times shares |
| Guided free cash flow | about $12.4B | Cash flow guidance less trailing capex of $3.14B |
| Gross debt | $60.68B | 10-Q, as of September 30, 2026 |
Method. Four investors with different philosophies, each on a different AI model, read one identical fact sheet and voted independently. A name needs three Buys to enter a basket. How the committee works.
Correction. This article first said neither token was investable, counting a missing sell quote for the xStocks token taken before regular US trading opened as a failure. Market makers quote thinly or not at all at that hour. We now judge that cost only during regular US market hours, and we have removed that verdict.
As of November 4, 2026, BagsCapital manages no outside capital and holds no position in CVS Health. Nothing here is investment advice.